Envisia® detects a genomic UIP pattern to improve ILD diagnostic and prognostic confidence


What is the test?

Why is usual interstitial pneumonia (UIP) important for suspected interstitial lung diseases (ILD)?

UIP is a critical factor in differentiating idiopathic pulmonary fibrosis (IPF) from other ILDs to determine appropriateness of antifibrotic treatment. Additionally, UIP is associated with poor prognosis across ILD subtypes.

What is Envisia?

Envisia classifier detects the genomic pattern of UIP using transbronchial biopsy (TBB) samples to help guide diagnostic and prognostic decisions. Envisia results must be interpreted in the context of other clinical factors such as demographics, clinical history, and high resolution CT (HRCT) findings. 

Play Video about Preview of "Watch brief overview of the Envisia classifier" video: a bronchoscopy procedure in the lung.

Watch brief overview of the Envisia classifier

Learn how to improve ILD diagnostic confidence with the Envisia classifier.

Who is a good candidate for the Envisia test?

Clinical Factors:

Have no known causes with suspected ILD


Probable UIP or indeterminate for UIP


Able to tolerate standard TBBx procedure

Envisia classifier results indicate either a positive or negative for UIP

Positive results

Screenshot of a patient report showing a negative Envisia test. Includes patient information and the result.
A positive result can give clinicians confidence that there is high likelihood of UIP given the high specificity of test and low likelihood of a false positive result.1

Negative results

Screenshot of a patient report showing a positive Envisia test. Includes patient information and the result.
A negative result can provide useful information in context of clinical factors and HRCT. Continued ILD diagnosis workup may be needed.
Photo of the Envisia Sample collection kit, with a box, multiple collection tubes, and an order form.

Sample collection and ordering

Samples are collected through standard forceps transbronchial biopsy (TBB). Test results delivered within two weeks to your computer or phone. 


1. Raghu G, et al. Lancet Respiratory Medicine. Apr 2019.